Track topics on Twitter Track topics that are important to you
ST. LOUIS, MO--(Marketwired - June 01, 2015) - Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") announced today that it is presenting a variety of new applications using the Company's proprietary mass spec imaging system and bioanalytical workflows at the 63rd
American Society of Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in St. Louis, MO. The eight posters to be presented by Protea scientists include the following:
"We are pleased to present a diverse set of applications using the imaging and bioanalytical workflows we've established at Protea," stated Greg Kilby, Ph.D., Protea's Vice President of Operations. He continued, "The ASMS conference is a great venue for us to exhibit our recent scientific developments that support our imaging and bioanalytical services, as well as showcasing the expanded applications of the LAESI instrument platform and release of the REDIchip target plate."
Also at the ASMS Annual Meeting, the Company announced the release of Redichip™ -- a proprietary, chip-based, matrix-free MALDI target plate enabling rapid and sensitive detection and quantitation of small molecules.
Protea's eight scientific posters will be presented in various sessions throughout the week. The Company's overall capabilities will be discussed with attending researchers in their corporate exhibit booth (Booth #123) at the conference.
For more information about the presentations at ASMS, visit our website at: https://proteabio.com/ASMS2015.
About Protea Biosciences Group, Inc.
Protea Biosciences Group, Inc. (OTCQB: PRGB) is a molecular information company providing innovative bioanalytical solutions to the pharmaceutical and life science industries. "Molecular information" refers to the generation and bioinformatic processing of very large data sets, obtained by applying the Company's technology to identify and characterize the proteins, metabolites, lipids and other biomolecules which are the byproducts of all living cells and life forms.
The Company is applying its technology to the development of next generation, "direct molecular imaging" technology and service capabilities that enable more rapid and comprehensive molecular profiling of human disease.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.Protea Biosciences Group, Inc.955 Hartman Run Road, Morgantown, WV 26505 USA Phone: 304.292.2226 Fax: 304.292.7101 NEXT ARTICLE